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Some diseases are neglected; others are
simply forgotten. Yaws belongs to the
second group. One of the first diseases to
be targeted for eradication on a global
scale, yaws almost disappeared, thanks to a
massive treatment program started in the
1950s that eliminated it from many
endemic areas. Then something went
wrong. The combat line somehow broke
down in several points, people focused on
other health emergencies, and yaws van-
ished from the political agenda. Not
surprisingly, the disease has now resurged
in several countries, where mass treatment
has had to be reintroduced.
Although rarely fatal, yaws leaves its
indelible mark on many of those touched,
horribly corroding their skin and bones.
Victims are mostly young children, who
end up disabled, stigmatized, and poor.
However, despite its visible effects, its
amenability for eradication, and all the
past efforts made to eliminate it, this
bacterial infection is still a menace. The
present situation calls for immediate action
to wipe yaws out forever. Its history, on
the other hand, has much to teach on how
eradication campaigns should—and
should not—be planned and conducted.
‘‘Yaws Begins Where the Road
Ends’’
Yaws (the name is believed to originate
from ‘‘yaya,’’ which in the indigenous
Caribbean language means sore), or fram-
boesia tropica (also known by the local
names of buba, pian, paru, and parangi)i sa
chronic, contagious, nonvenereal infection
caused by the spirochete Treponema pallidum
subspecies pertenue. A disease of the poor,
yaws mainly affects populations living in
rural areas of warm and humid subtropical
countries, where conditions of overcrowd-
ing, poor water supply, and lack of
sanitation and hygiene prevail. The orig-
inal distribution of the infection spanned
across Africa, Asia, South America, and
Oceania, but past eradication campaigns
have strongly reduced the geographic
extension and global burden; a few foci
resist, however, notably in South-East Asia
(Indonesia, Timor-Leste, Papua New
Guinea) and Africa (Ghana, Republic of
the Congo). Direct skin-to-skin contact is
the main route for transmission, together
with breaks in the skin caused by injuries,
bites, or excoriations [1]. According to
older accounts, flies may also play a role as
vectors for transmission [2].
Clinical manifestations occur in three
distinct phases. At the primary, early stage,
a papular ‘‘raspberry-like’’ lesion develops
after three to four weeks of incubation at
the Treponema inoculation site (usually a
leg) and ulcerates; this ‘‘mother yaw’’
generally heals spontaneously after a few
months, although it can last a year or
longer. During the incubation period,
spirochetes invade the lymphatics and
spread across the body. The secondary
stage is characterized by the widespread
dissemination of smaller skin lesions that
teem with treponemes. Goundou, an
osteitis characterized by impressive swell-
ings on each side of the nose and reported
sporadically, mostly from West Africa, is
recognized as a form of secondary-stage
yaws [3]. At the third (late) stage, whose
onset can be after a period of latency
lasting several years, bone, cartilage, and
soft tissue destruction may occur, jointly
with severe skin ulceration and painful
hyperkeratosis on palms and soles, leading
to gross deformities of the legs, skull, nose,
palate, and upper jaw, with consequent
irreversible disabling and disfiguration
(Figures 1–3). This stage is not contagious,
and develops in 10% of untreated individ-
uals.
Children under 15 years are the main
yaws victims, with peak incidence in the
six- to ten-year-old age range. Treatment
of early-stage yaws is very simple and
inexpensive, as it only requires a single
intramuscular shot of long-lasting ben-
zathine penicillin that costs as little as 30
US cents. Recurrence due to re-infection
or relapse is rare, and only a few penicillin
treatment failures have been documented
to date, with tetracycline, doxycycline, or
erythromycin all being viable alternatives.
There is no vaccine, although the avail-
ability of the fully sequenced syphilis
spirochete genome could lead to impor-
tant progress in this direction [4,5]. Thus,
prevention relies on early diagnosis and
treatment of affected individuals and their
contacts, and on implementing personal
and group hygiene [1].
An Old Travel Companion
Treponemal infections form a rather
compact cluster. The venereal-transmitted
syphilis is by far the best known, owing to
its long-lasting presence in Western soci-
eties, whereas the nonsexual, tropically
distributed yaws, bejel (or endemic syph-
ilis), and pinta have received relatively
little attention in medical culture. Different
T. pallidum subspecies cause syphilis (subsp.
pallidum), bejel (subsp. endemicum), and yaws
(subsp. pertenue). Pinta, a mild disease
characterized by loss of skin pigmentation,
is caused by T. carateum. All T. pallidum
subspecies are morphologically identical
and cross-react to the same serological
tests; only subtle genetic differences have
been identified that permit them to be
distinguished, leaving open the question of
how such a limited variation can translate
into the observed differences in pathogen-
esis [6]. The lack of reliable serological or
morphological tests to distinguish T.
pallidum subspecies obviously limits diag-
nostic accuracy, which can have serious
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ment for a pregnant woman with burnt-
out yaws and one with active syphilis
should be different, and assigning the
wrong treatment may result in a negative
outcome [7]. It is therefore not surprising
that an important avenue of current
research on treponematoses focuses on
the in-depth analysis of the T. pallidum
genome, in the attempt to identify and
decipher determinants of host specificity,
pathogenicity, and virulence among the
different subspecies (e.g., [8,9]). Future
advances in distinguishing between the
subspecies using DNA polymorphisms
may lead to serological tests that could
be used in the field, facilitating disease
control and eradication efforts by permit-
ting the monitoring of its continued impact
on populations.
The origin of yaws, as that of the other
treponematoses, is still debated. A recent
study by a US and Canadian research
team, however, has provided fresh insight
into the puzzle [10]. These scientists, led
by Kristin Harper from Emory University
in Atlanta (Georgia, US), used data from a
large set of pathogenic Treponema strains of
disparate geographic origin—including
two strains of yaws isolated from remote
inhabitants of Guyana in South Amer-
ica—to reconstruct phylogeny and dissem-
ination history. ‘‘[E]vidence is consistent
with the hypothesis that yaws is an
heirloom disease in humans, one caused
by a pathogen that infected our anthro-
poid ancestors and has evolved with our
species,’’ wrote Harper and colleagues
[10], claiming that the presence of yaws
in wild populations of gorillas, chimpan-
zees, and baboons further supports this
theory, although a more recent cross-
species transfer event between humans
and nonhuman primates cannot be com-
pletely ruled out. According to the derived
phylogenetic tree, T. pallidum probably first
sprouted in the Old World, in the form of
nonvenereal infection (yaws), and from
there it traveled with humans along their
journey to the Middle East and Eastern
Europe, changing to endemic syphilis, and
then to the Americas, in the form of New
World yaws. In the Americas, the causa-
tive agent of venereal syphilis, T. pallidum
subsp. pallidum, arose from yaws, as
revealed from the genetic analysis of two
subsp. pertenue strains gathered in Guyana,
and was reintroduced back into in the Old
World, possibly by the first European
explorers. It is also possible that a
progenitor of syphilis actually arose in
the New World, and thus syphilis itself did
not arise until the explorers returned to
Europe. These findings, therefore, lend
support to the so-called ‘‘Columbian
theory’’ of the origin of syphilis, which
postulates that Christopher Columbus’
crew members unwittingly brought the
disease back to Europe when returning
from their very first discovery voyage.
Not everyone agrees, however. Com-
menting on Harper’s group’s findings,
Connie Mulligan and colleagues objected
that when the genetic data used to build
the phylogenetic tree of T. pallidum sub-
species are subjected to closer inspection, it
appears that no true evolutionary order
can be inferred [11]. ‘‘Harper et al. have
proposed that the syphilis treponeme has
evolved more recently in history from New
World yaws strains. However, further
analysis [by Mulligan and colleagues] is
consistent with earlier reports, which do
not support an older origin of yaws but a
relatively parallel evolution of the three
subspecies,’’ said Treponema expert Arturo
Centurion-Lara, from the University of
Washington at Seattle (Washington, US).
‘‘Therefore, we should exercise caution
when interpreting biological observations
from an evolutionary point of view.’’
When the rapid disappearance of yaws is
considered (see below), archiving strains of
yaws and the other nonvenereal trepone-
matoses would allow larger comparative
genetic studies, thus helping further re-
search on the history of this disease by
providing a data reference tool usable in
solving the problem of just how old yaws is
and where it came from.
Eradication: Early Attempts,
Failure, Lessons, and New
Hopes
Yaws has been the second disease ever
to be targeted for eradication (defined as
zero incidence and no evidence of trans-
Figure 1. A 45-Year-Old Woman from the Ivory Coast with Tibial ‘‘Saber Deformity’’ as
a Result of Late Tertiary Yaws Infection. A saber shin deformity is an abnormality of the tibia
characterized by marked anterior bowing of the lower leg. This defect may be seen in some
children with congenital syphilis and in patients with yaws. Credit: US Centers for Disease Control
and Prevention/Dr. Peter Perine.
doi:10.1371/journal.pntd.0000275.g001
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among children under five years in areas
that were earlier endemic) on a global
scale. (The first one was, unsuccessfully,
yellow fever, in 1915.) From 1952 to 1964,
the Global Yaws Control Programme was
launched by the World Health Organiza-
tion (WHO) in partnership with UNICEF,
treating some 300 million people in 46
countries and reducing the global levels of
the disease by 95%. Strategy of the early
yaws eradication program was based on
injection of either benzathine penicillin or
procaine penicillin G, and was changed in
the campaign’s earliest phases to include
presumptive therapy for household con-
tacts after it was realized that treatment of
overt cases alone produced only a transient
reduction in incidence. Treatment cover-
age varied depending on the prevalence of
yaws in a particular area. Where preva-
lence was less than 5%, only active cases
and their contacts were treated; while in
areas with levels of endemicity greater than
10%, the entire population was treated [1].
Where prevalence ranged between 5% and
10%, all prepubertal children, adults af-
fected by active disease, and obvious
contacts received treatment [1].
When the campaign began—one of the
first programs launched by WHO soon
after its establishment in 1948—an esti-
mated 50 to 100 million people were
afflicted by yaws worldwide. Today’s
prevalence is unknown, because yaws
cases are no longer obligatorily notified
to WHO, and many countries where the
disease was previously endemic stopped
recording them. In the 1990s, estimated
global prevalence was at 2.5 million, with
460,000 new cases [12]. ‘‘The last infor-
mation on yaws was in 1990. Since then,
there has not been any official notification
of the disease. We are currently working
with the different regions to identify the
remaining endemic countries and foci for
targeted elimination efforts,’’ said Kingsley
Asiedu, from the WHO’s Department of
Control of Neglected Tropical Diseases in
Geneva. Currently, about 5,000 new cases
are reported annually in South-East Asia,
and as many as 26,000 cases were
reported in 2005 in Ghana [12]. In
Central African countries, yaws has a
particularly high prevalence among for-
est-dwelling Pygmy communities, a fact
hinting at their exclusion from govern-
ment health services [13]. In the Americas,
the situation is less clear. Yaws has been
eliminated from most of the continent
(e.g., [14]), but a survey conducted in 2000
in rural Guyana indicated a prevalence of
skin yaws similar to that recorded in 1952
in Haiti, the country with the highest
prevalence in the Western Hemisphere
before the eradication campaign began
[15]. On the other hand, surveys carried
out in 2006 and 2007 in endemic yaws
territory in Guyana demonstrated no
active cases of the disease [10]. ‘‘Unfortu-
nately, there are no certain data on the
status of yaws in the Americas. The
notification of new cases can be signifi-
cantly underestimated. In the absence of
Figure 2. A Nigerian Boy with Yaws (Late 1960s). Yaws causes ulcerative skin lesions, and is
found in areas where poor sanitation exists. Yaws was prevalent in some of the relief camps set
up during the Nigerian-Biafran war (1967–1970). Credit: US Centers for Disease Control and
Prevention/Dr. Lyle Conrad.
doi:10.1371/journal.pntd.0000275.g002
Figure 3. Confluent Papillomata with an Ulceration of the Lower Leg of Several Years
Duration in a Yaws Patient. Credit: US Centers for Disease Control and Prevention/Dr. Peter
Perine.
doi:10.1371/journal.pntd.0000275.g003
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latent form, it is difficult to consider yaws
as eliminated,’’ said Mariella Anselmi, of
the Centro de Epidemiologia Comunitaria
y Medicina Tropical (CECOMET) in
Esmeralda, Ecuador. ‘‘The sporadic cases
still recorded in Guyana confirm the
persistence of the latent form and thus,
given the high contagiousness of lesions,
the possibility of epidemic episodes if
adequate surveillance is lacking.’’ In terms
of the efficacy of treatment in driving
down prevalence of the infection, a study
conducted in rural Guyana has shown that
treatment of yaws in children less than 14
years of age with an oral penicillin V
therapy lasting seven to ten days led to a
71% drop in prevalence. These results
demonstrate that a simple but targeted
treatment regimen can dramatically re-
duce the prevalence of yaws in an endemic
community and can also effectively treat
individuals with active yaws [15].
‘‘The failure to achieve complete erad-
ication was due to multiple reasons,
notably the premature integration of yaws
control activities into the general health
services and the disappearance of support
for yaws control,’’ said Asiedu. Basically,
the dedicated vertical programs were
dismantled before the final blow could be
struck, and the resources and commitment
for yaws and its surveillance activities also
disappeared. ‘‘[Yaws] programs have been
deficient in failing to aggressively seek and
contain yaws cases and contacts after mass
treatment campaigns reduced yaws prev-
alence to low levels,’’ wrote Donald
Hopkins in 1976, slightly before smallpox
global eradication was certified and while
yaws was already resurgent [16].
At its eleventh meeting last October, the
International Task Force for Disease
Eradication (ITFDE)—a group of experts
formed at the Carter Center (Atlanta,
Georgia, US) in 1988 in the wake of
enthusiasm that followed the eradication
of smallpox—reviewed the yaws case.
ITFDE concluded that ‘‘[t]he continued
occurrence of yaws and other endemic
treponematoses, despite availability of an
effective, stable and inexpensive treatment
and a simple means of diagnosis in the
field, is lamentable testimony to lack of
political will, inadequate funding, and
persistent weakness in primary health care
systems of affected countries’’ [17]. This
view is shared by many, including Jai
Narain, Director of the Department of
Communicable Diseases of WHO’s Re-
gional Office for South-East Asia. ‘‘Un-
fortunately, yaws remains among the most
neglected diseases and there is little global
attention or focus on this disease, although
it primarily affects the most poor and
vulnerable sections of the society—the
tribal or indigenous people living far away
from mainstream,’’ said Narain. ITFDE
lamented that ‘‘[t]he current status of
knowledge of the extent of yaws is very
poor’’ and suggested that ‘‘[t]he World
Health Organization should publicize the
currently known and unknown status of
surveillance for this disease in each of the
remaining suspected endemic countries,
and encourage mapping and more de-
tailed reporting of surveillance data’’ [17],
thus playing a steering role in addressing
this curable and preventable disease.
WHO, it must be stressed, is responding
to the appeal. In a consultation round-up
held recently at the organization’s head-
quarters in Geneva, experts and officers
from the health ministries of those coun-
tries where yaws is still a menace agreed
on a basic agenda for future action [18].
The agenda includes a rapid assessment of
the burden of disease and infection in
selected countries; revival of activities to
control yaws; and establishment of an
elimination program for yaws, directed by
WHO in the context of its larger Neglect-
ed Tropical Diseases initiative. Elimina-
tion of clinical cases (zero cases) supported
by active case-finding and serological
surveys has been declared as the goal,
but no timeline has been set.
Although it is generally agreed that
political and financial inertia are the
biggest obstacles to interrupting transmis-
sion of yaws, some eradication experts
point out that biological and medical
barriers also exist. For example, although
it is usually claimed that humans are the
only reservoir of infection, 17% of the
members of a wild gorilla population in
the Republic of Congo presented typical
yaws skin lesions [19]. Yaws may also
affect African baboons, and widespread
serological testing of wild populations has
been performed; genetic analyses of a
strain collected from a Guinean baboon
shows that it is closely related to human
yaws strains [10]. If complete eradication
is to be enforced, nonhuman reservoirs
need to be cleared as well. Successful
treatment campaigns have already been
carried out on primates against various
infectious diseases; in the case of yaws,
affected baboons were darted and treated
with penicillin and an additional antibiotic
[20]. In parallel, more information is
needed on the way pathogens cross-
transmit between humans and primate
populations, so that suitable strategies to
prevent disease spreading and/or resur-
gence may be developed. As for humans,
untreated victims may remain infective for
months, favoring the spread of treponemes
within populations. A vaccine is still
lacking, and so is a reliable test able to
distinguish yaws from the various other
treponematoses and monitor its impact on
populations, as discussed earlier. Further-
more, some researchers noted, the recur-
rent shortage of benzathine penicillin G in
North America due to production prob-
lems could make mass treatment difficult
([15]; see also the American Society of
Health-System Pharmacists’ Web site at
http://www.ashp.org/), and the drug’s
storage requirements may limit its use in
tropical areas that lack electricity. ‘‘Some
of the issues and challenges that have
hampered yaws eradication historically
include the lack of an effective mechanism
for surveillance and case detection, limited
political commitment and resources, lim-
ited capacity of general health staff to
recognize and treat yaws, ensuring drug
supply and logistics management, creating
community awareness through appropri-
ate advocacy/IEC [Information, Educa-
tion, and Communication] campaigns and
extending the services to remote and hard-
to-reach areas,’’ a recent WHO report
remarked [21].
Despite these constraints, however,
recent evidence from India suggests that
yaws can be effectively controlled, at least
at the national level, and even swept out if
sufficient energy is applied [22,23]. ‘‘Yaws
had been declared to be eliminated from
India on Sept 19, 2006 as no case of the
disease was reported since 2003. The new
target set for yaws eradication from India
is year 2008,’’ said Chandrakant Lahariya,
from the Gajara Raja Medical College in
Gwalior, India. ‘‘The elimination has been
achieved based on a two-pronged strategy
which primarily consisted of: first, active
case finding and treatment of cases and
prophylaxis of the household contacts
using a single injection of long acting
penicillin; second, community mobilisa-
tion. The programme used a campaign
approach—health workers went village to
village every six months looking for yaws
cases and offering treatment/prophylaxis
to those needing it,’’ added Narain. ‘‘The
program is still functioning in the coun-
try,’’ concluded Lahariya. ‘‘The biannual
independent appraisals of the activities
under this program are also done, and the
last one was conducted in 2006. The sero-
surveillance activities in the selected dis-
tricts in the children aged less than five
years are also being done to ensure that
the T. p. pertenue is not present in the
community,’’ he said.
As for South-East Asia, attention is now
shifting to the last two countries in the
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donesia and Timor-Leste [21]. ‘‘Indonesia
has reported 6,461 cases during 2006 from
17 provinces with majority of cases coming
from Nusa Tengarra Timur, Papua, West
Papua, Maluku and SE Sulawesi,’’ said
Narain. ‘‘These are also the areas which
are more remote, relatively inaccessible
and less economically well off. In Timor-
Leste, the health care workers engaged in
immunization campaigns have reported
clinical yaws among 1%–2% of children
below five, during 2003–2006,’’ he said.
Both these countries are fully committed
to yaws eradication and have developed
national strategies and operational plans,
explained Narain. Many activities such as
health care worker training are being
carried out. Both countries are also trying
to mobilize resources since the constraints
of funding remain a major issue, not only
for case-finding operations but also for
treatment of cases and contacts. ‘‘If
additional (modest) funds become avail-
able, we are hopeful that the target can be
achieved within next five years in both
Indonesia and Timor-Leste. However this
needs the enhanced collaboration and
partnership with national and internation-
al partners,’’ said Narain. Lahariya, on his
side, thinks that some philanthropic orga-
nization should come in and lead the
activities of yaws eradication programs in
Indonesia and Timor-Leste through suffi-
ciently funded vertical programs. ‘‘These
are smaller geographical regions, the total
fund required for the activities would be
small, there is sufficient expertise available
in the region: these are the factors to
facilitate early yaws eradication from these
regions,’’ said Lahariya.
‘‘We are motivated by India’s experi-
ence but at the same time, we also know
the difficulties the elimination and eradi-
cation efforts entail,’’ said Asiedu. ‘‘We
have to adapt the strategies to different
countries’ situations. To make eradication
efforts more easier, we may also need to
look at new technologies (diagnostics and
medicines) to help achieve elimination and
eventually eradication. Penicillin is still
effective but we also need to research into
new antibiotics particularly oral ones.’’
The insistence on the treatment of sub-
clinical infections (contacts) as well as
obvious cases should be rigorously imple-
mented, Asiedu explained. ‘‘Treating the
sick alone is not sufficient. Today, there
are more favorable opportunities to allow
integration of yaws activities into the
existing general health services.’’
Building on a New Awareness
Besides the general criteria of biological
and technical feasibility, costs and benefits,
and societal and political considerations,
each disease eradication attempt has its
own peculiarities, which should be care-
fully considered in order to achieve success
[24]. Yaws, in this regard, is a one-of-a-
kind opportunity, because a lot can be
learnt from past practical efforts, with less
need for speculation. Networking, for
example, is now considered a key element
for a new strategy to beat the flesh-eating
foe. ‘‘There is no international network on
yaws eradication like you will find with
polio and Guinea worm. We need to build
the network and develop the necessary
partnership for tackling yaws in a sustain-
able manner,’’ remarked Asiedu. ‘‘Clearly,
greater collaboration, networking and
resource mobilisation is required in order
to achieve yaws eradication globally or
even regionally,’’ agreed Narain. Besides
looking at how India achieved success,
Asiedu said, activities from other eradica-
tion programs like polio, Guinea worm,
and leprosy will also be considered.
Indeed, collaboration with existing pro-
grams could allow resources to be shared
and facilitate elimination and surveillance
activities. There is also a clear need for
increased advocacy and generation of
interest, both in the disease itself and in
engaging countries.
‘‘What seems most interesting about the
renewed effort in South-East Asia is that it
is aggressively targeting both cases and
their contacts, for which there seems to be
evidence that this could overcome the
earlier challenges,’’ said Bruce Aylward,
Director of the Global Polio Eradication
Initiative (http://www.polioeradication.
org/). ‘‘The disease is extremely amenable
to eradication epidemiologically, techno-
logically, historically and from political
commitment point of view. We believe also
that efforts on yaws eradication could be an
entry point for primary health care for the
most marginalised populations,’’ said Nar-
ain. ‘‘I strongly believe that yaws can still be
eradicated from the world in the next five
years,’’ confirmed Lahariya. ‘‘The fortu-
nate thing for yaws is that we don’t need
whopping amount to realize our efforts.
The total amount of money required to
achieve yaws eradication would be only a
small fraction of what is being spent for
polio eradication annually.’’
So, after all, the world is being given a
new chance to get rid of yaws forever—an
accomplishment that could certainly benefit
future eradication campaigns with a legacy
of positive impetus. ‘‘I think that when polio
eradication is being proven difficult, achiev-
ing yaws eradication will be a big morale
booster for the health workforce,’’ summa-
rized Lahariya. ‘‘Ultimately eradication of
another disease—take for example that of
smallpox in 1978—would by itself be an
achievement for public health!’’ Narain
chimed in. The other side of the coin is that
a second failure against this vincible enemy
could cast discredit and mistrust on other
ongoing and future eradication efforts,
directed against more pernicious and less
vulnerable pathogens. Let’s just hope this is
not the case.
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